Valuation: Novavax, Inc.

Market Cap 1.35B 1.18B 1.09B 1.01B 1.9B 130B 1.93B 13.08B 5.13B 63.7B 5.07B 4.96B 219B P/E 2026 *
-17.4x
P/E 2027 * -32.3x
Enterprise Value 1.57B 1.38B 1.27B 1.17B 2.21B 151B 2.24B 15.2B 5.96B 74.03B 5.89B 5.76B 255B EV / Sales 2026 *
3.83x
EV / Sales 2027 * 6.4x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day-3.29%
1 week-11.56%
Current month-16.35%
1 month-12.44%
3 months-9.11%
6 months-3.90%
Current year+17.26%
1 week 7.84
Extreme 7.845
8.92
1 month 7.84
Extreme 7.845
10.12
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 22/01/2023
Director of Finance/CFO 60 15/08/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Director/Board Member 73 05/08/2010
Director/Board Member 66 31/10/2018
Director/Board Member 60 15/06/2020
Date Insider Type Main position Quantity % Market Cap.
20/06/26 Fiscal year

Director

37,760 0.0230%
20/06/26 Fiscal year

Director

37,760 0.0230%
20/06/26 Fiscal year

Director

37,760 0.0230%
Change 5-day change 1-year change 3-year change Capi.($)
-4.02%-11.56%+9.90%-2.23% 1.35B
-0.49%-3.58%-0.84%+2.13% 49.18B
-3.10%-1.94%+369.52%+572.60% 39.58B
-0.46%+2.18%+6.39%+61.01% 34.69B
-1.14%-1.90%+26.94%-9.56% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.54%-5.08% - - 16.21B
-1.82%-0.43%+70.92%+113.82% 15.36B
+1.17%+3.10%+15.87%+16.79% 14.05B
-2.25%+0.05%+19.01%-32.83% 13.02B
Average -1.42%-1.35%+57.58%+83.75% 24.5B
Weighted average by Cap. -1.01%-0.44%+75.71%+117.92%

Financials

2026 *2027 *
Net sales 410M 359M 332M 305M 576M 39.53B 586M 3.97B 1.56B 19.34B 1.54B 1.51B 66.64B 258M 227M 209M 193M 363M 24.92B 369M 2.5B 982M 12.2B 971M 949M 42.02B
Net income -79.31M -69.51M -64.25M -59.09M -111M -7.65B -113M -768M -301M -3.74B -298M -291M -12.89B -43.22M -37.88M -35.02M -32.21M -60.77M -4.17B -61.74M -419M -164M -2.04B -162M -159M -7.03B
Net Debt 219M 192M 177M 163M 308M 21.12B 313M 2.12B 832M 10.33B 822M 804M 35.6B 303M 266M 246M 226M 426M 29.24B 433M 2.94B 1.15B 14.31B 1.14B 1.11B 49.29B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
20/07/26 US$7.880 -4.02% 3,002,729
17/07/26 US$8.210 -0.36% 2,265,585
16/07/26 US$8.240 -2.25% 2,403,348
15/07/26 US$8.430 +0.12% 2,537,759
14/07/26 US$8.420 -5.50% 3,798,121
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
8.210USD
Average target price
14.11USD
Spread / Average Target
+71.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock